Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 45.8% in May

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) saw a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 46,900 shares, a decline of 45.8% from the May 15th total of 86,500 shares. Based on an average trading volume of 88,200 shares, the short-interest ratio is currently 0.5 days. Currently, 0.5% of the shares of the stock are sold short.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Avalo Therapeutics in a research note on Tuesday, March 25th. They issued a "buy" rating and a $23.00 target price for the company. Piper Sandler assumed coverage on shares of Avalo Therapeutics in a research note on Friday, February 28th. They set an "overweight" rating and a $48.00 price target for the company. Stifel Nicolaus assumed coverage on shares of Avalo Therapeutics in a research note on Tuesday, March 25th. They set a "buy" rating and a $36.00 price target for the company. Wedbush reissued an "outperform" rating and set a $18.00 price target on shares of Avalo Therapeutics in a research note on Thursday, March 20th. Finally, HC Wainwright raised shares of Avalo Therapeutics from a "hold" rating to a "buy" rating and set a $15.00 price target for the company in a research note on Monday, June 2nd. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Avalo Therapeutics has an average rating of "Buy" and a consensus target price of $30.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Allostery Investments LP boosted its holdings in shares of Avalo Therapeutics by 46.1% in the first quarter. Allostery Investments LP now owns 107,141 shares of the company's stock valued at $858,000 after buying an additional 33,827 shares during the period. ADAR1 Capital Management LLC acquired a new position in Avalo Therapeutics during the first quarter worth $80,000. Nantahala Capital Management LLC acquired a new position in Avalo Therapeutics during the first quarter worth $7,209,000. Affinity Asset Advisors LLC boosted its holdings in Avalo Therapeutics by 19.3% during the first quarter. Affinity Asset Advisors LLC now owns 657,154 shares of the company's stock worth $5,264,000 after purchasing an additional 106,389 shares during the last quarter. Finally, RWA Wealth Partners LLC acquired a new position in Avalo Therapeutics during the first quarter worth $2,505,000. Institutional investors and hedge funds own 87.06% of the company's stock.

Avalo Therapeutics Stock Performance

Shares of NASDAQ AVTX opened at $4.84 on Friday. The firm has a 50 day moving average price of $4.46 and a 200 day moving average price of $6.71. Avalo Therapeutics has a 52-week low of $3.39 and a 52-week high of $16.00.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.18). On average, sell-side analysts forecast that Avalo Therapeutics will post -19.07 earnings per share for the current fiscal year.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.